Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Registry-Based Extension of Protocol V503-001 in Countries With Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, Immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine as Administered to 16- to 26- Year-Old Women

Next Previous
Trial Profile

A Registry-Based Extension of Protocol V503-001 in Countries With Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, Immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine as Administered to 16- to 26- Year-Old Women

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human Papillomavirus 9-valent recombinant vaccine Merck (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
  • Indications Cervical cancer; Genital warts; Human papillomavirus infections; Vulvovaginal cancer
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 30 Jul 2025 This trial has been terminated in Sweden ,According to Clinical Trials Information System record
  • 30 Nov 2023 The study duration is increased to 30 years, and thus the timeline of primary end-point is also increased from 16 to 30 years.
  • 30 Nov 2023 Planned End Date changed from 1 Jan 2024 to 1 Jan 2040.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top